The Phase 3 FLAIR study evaluates monthly i.m. Long Acting (LA) cabotegravir (CAB) and rilpivirine (RPV) as maintenance therapy in suppressed HIV infected adults over 48 weeks and demonstrated non-inferiority to 3 drug daily oral ART. A total of 3/283 (1%) participants (PTS) who received CAB+RPV LA had confirmed virologic failure (CVF). All 3 CVFs occurred among 8 PTS in that study arm with subtype A1 virus and all 3 had baseline integrase (IN) substitution L74I, as did 2/5 PTS who maintained viral suppression. All 8 PTS with subtype A1 virus were sensitive to CAB at baseline. 174/283 (61%) PTS in the LA arm had subtype B, 7% with L74I without CVF. Given the apparent clustering of CVF among A1 and presence of L74I, we sought to determine the impact of L74I and subtype A1 compared to subtype B IN on CAB sensitivity.
IN genotypes and phenotypic sensitivity to CAB were generated at Monogram Biosciences. Site directed mutants were generated in subtype B NL4-3 and a consensus A1 IN sequence derived from the 3 CVF baseline IN sequences. In vitro susceptibility to CAB was assayed and compared across virus subtypes. The in vitro durability of CAB was tested against bulk infected cultures at various CAB concentrations for 3 weeks.
All baseline, A1 IN sequences (8/283 subjects) were sensitive to CAB with IC50 fold-change (FC) ranging from 0.7-1. The 3 CVF sequences at the failure timepoint had CAB FC IC50 values of 5.22 – 9.36 and substitutions at L74I and G140R or Q148R. The site-directed mutants L74I/G140R (FC 0.87 A1 vs 0.58 B) or L74I/Q148R (FC 4.1 A1 vs 4.4 B) in the A1 background resulted in similar IC50 FC compared to subtype B background. Across both subtypes, time to viral breakthrough was similar at the lowest CAB concentration (1nM) and no viral breakthrough was detected at 3 weeks for CAB concentrations of 5nM or 410nM (1xPAEC90). The genotypes of the breakthrough viruses will be presented.
The FLAIR study demonstrated CAB+RPV LA was noninferior to oral ART at Week 48 with 3 CVFs harboring HIV subtype A1 with baseline L74I. In vitro virologic assessments do not indicate a differential sensitivity to CAB between subtypes A1 or B in viruses containing IN mutations observed in the CVFs. However, our evaluations cannot determine if HIV subtype A1 with L74I has greater likelihood of selection of additional INSTI mutations under selection pressure. Other factors may contribute to the risk of CVF and require further investigation.